(+)-Erinacin A (1, 5 and 10 mg/kg, i.p.; single dose) inhibits neuronal cell death in SAM rats with transient stroke and suppresses the expression of inflammatory cytokines in SAM brain tissues with transient stroke[4].
(+)-Erinacin A (1, 2 and 5 mg/kg, i.p.; once a day for 5 days) significantly reduces tumor volume in DLD-1 xenograft mice[5].
| Animal Model: | DLD-1 xenograft mouse model[5]. |
| Dosage: | 1, 2 and 5 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) once a day for 5 days |
| Result: | Inhibited tumor volume by 60%, 32% and 26%.
|
| Animal Model: | SAM rats with transient stroke[4]. |
| Dosage: | 1, 5 and 10 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) single dose |
| Result: | Induced NeuN immune response in the entire brain region of SAM rats, and increased the number of NeuN cells.
Inhibited the activation of iNOS and p38/MAPK pathways and the expression of CHOP and nitrotyrosine proteins in rat brain tissue.
|
